0001437749-15-016753.txt : 20150901 0001437749-15-016753.hdr.sgml : 20150901 20150901185314 ACCESSION NUMBER: 0001437749-15-016753 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150831 FILED AS OF DATE: 20150901 DATE AS OF CHANGE: 20150901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMPAX LABORATORIES INC CENTRAL INDEX KEY: 0001003642 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 650403311 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 30831 HUNTWOOD AVENUE CITY: HAYWARD STATE: CA ZIP: 94544 BUSINESS PHONE: 510-240-6000 MAIL ADDRESS: STREET 1: 30831 HUNTWOOD AVENUE CITY: HAYWARD STATE: CA ZIP: 94544 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL PHARMACEUTICAL CORP \DE\ DATE OF NAME CHANGE: 19951117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FLEMING NIGEL CENTRAL INDEX KEY: 0001245365 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34263 FILM NUMBER: 151088304 MAIL ADDRESS: STREET 1: 392 DURANT WAY CITY: MILLVALLEY STATE: CA ZIP: 94941 4 1 rdgdoc.xml FORM 4 X0306 4 2015-08-31 0001003642 IMPAX LABORATORIES INC IPXL 0001245365 FLEMING NIGEL C/O IMPAX LABORATORIES, INC. 30831 HUNTWOOD AVENUE HAYWARD CA 94544 1 Common Stock 2015-08-31 4 S 0 6166 41.02 D 8200 D Common Stock 2015-08-31 4 M 0 10000 20.30 A 18200 D Common Stock 2015-08-31 4 S 0 10000 41.02 D 8200 D Common Stock 2015-08-31 4 M 0 8000 17.99 A 16200 D Common Stock 2015-08-31 4 S 0 8000 41.02 D 8200 D Common Stock 2015-08-31 4 M 0 5000 20.90 A 13200 D Common Stock 2015-08-31 4 S 0 5000 41.02 D 8200 D Stock Option (Right to Buy) 20.30 2015-08-31 4 M 0 10000 0 D 2020-05-26 Common Stock 10000 0 D Stock Option (Right to Buy) 17.99 2015-08-31 4 M 0 8000 0 D 2023-05-15 Common Stock 8000 4000 D Stock Option (Right to Buy) 20.90 2015-08-31 4 M 0 5000 0 D 2022-05-23 Common Stock 5000 5000 D The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $40.34 to $42.15 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. 100% of the shares subject to the option are fully vested and exercisable. Of the 12,000 shares underlying the options, 8,000 of the shares subject to the option are fully vested and exercisable. The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person. /s/ Mark A. Schlossberg, by Power of Attorney 2015-09-01